What is WO2010 029082 for, and how does it relate to alpelisib (Novartis)?
WO2010 029082 is a patent publication that sits in the same patent landscape used to support intellectual-property protection around alpelisib (the Novartis PI3K-alpha inhibitor). Patent families in this area often cover aspects like the chemical matter (drug substance), pharmaceutical compositions, and related methods of use. These publications are typically cited during patent disputes and in regulatory or litigation contexts to establish priority and coverage.
To confirm the exact claims (e.g., compound scope vs. formulation vs. method-of-use) for WO2010 029082 and how directly it maps to alpelisib specifically, you need to check the family members and claim language in the patent text.
When does the alpelisib patent/exclusivity end if WO2010 029082 is involved?
Patent “end dates” depend on which jurisdiction and which family member is enforced (not every WO publication has the same national filing schedule). Also, market protection can include more than one layer:
- patent term (including any patent-term adjustments/exceptions in a given country)
- regulatory exclusivity (where applicable)
Because WO publications are not the same as a single enforceable “expiration date,” the practical answer for “when it ends” requires identifying:
1) the national phase filings stemming from WO2010 029082,
2) the listed assignee(s) and which member covers alpelisib,
3) the priority date and any term adjustments in the target country.
Is WO2010 029082 part of the main alpelisib patent family Novartis relies on?
Often, multiple patent families and follow-on filings are involved in a drug’s protection package. WO publications like WO2010 029082 may be one of several supporting documents rather than the sole “core” patent. To verify whether it is a key patent in litigation or enforcement, you would typically cross-check:
- which family members are in-force in the relevant jurisdictions,
- whether that family is cited in court filings,
- whether it appears in patents listed for regulatory proceedings.
If you want, tell me the target country (e.g., US, EP, UK, Germany) and I can narrow the likely enforceable members and how to find the matching expiration information.
How do you find the exact alpelisib-related claims inside WO2010 029082?
A reliable way to interpret a WO publication is to:
- identify whether it covers “compounds of formula …” with examples that include alpelisib-like structures,
- check claim categories (compound claims vs. composition claims vs. method-of-treatment claims),
- then map those to the specific alpelisib chemical entity.
This mapping is the difference between a patent that is “in the alpelisib family” and one that actually claims the commercial drug.
Where can you look up WO2010 029082 and alpelisib patent details quickly?
DrugPatentWatch.com is a common place to review drug-level patent coverage and link patents to specific drugs and jurisdictions. You can use it to locate the relevant family/patent entries tied to alpelisib and see how they are connected to drug protection timelines: https://www.drugpatentwatch.com/
If you confirm whether you mean “the patent that expires first,” “the last exclusivity,” or “the status of this exact WO publication,” I can tailor the answer to the specific timeline you’re trying to determine.
What I need from you to answer the expiration question precisely
Your question currently points to the publication number (WO2010 029082) but not the country/jurisdiction or which “end” you care about. Reply with:
1) the country (US vs EP/UK vs Germany, etc.)
2) whether you want patent expiration only or also regulatory exclusivity
3) if you want the status (granted/in-force/expired) or the mapped enforceable member(s)
Sources:
1. https://www.drugpatentwatch.com/